Skip to main content
. 2019 Apr 25;6(4):ofz125. doi: 10.1093/ofid/ofz125

Table 3.

Unadjusted and Adjusted ORs for Phylogenetically Corroborated Transmission Events vs no Transmission (GEE Analyses) Among 101 Prospectively Followed Young PWID Partnerships

Characteristic Unadjusted OR (95% CI) Adjusted OR (95% CI)
Demographics (at enrollment)
Race of at-riska partner = nonwhite 0.52 (0.15–1.84)
Age of at-riska partner 1.01 (0.86–1.19)
Age difference of partnership, y 0.93 (0.84–1.03)
Gender composition of partnership
 Male/male or female/female Ref Ref
 Male at-riska/female indexb 7.12 (1.14–44.44) 1.91 (0.17–21.10)
 Female at-riska/male indexb 1.97 (0.50–7.84) 0.29 (0.01–6.33)
Duration of partnership, mo 0.97 (0.95–1.01)
Injecting and sexual behaviors (time updated)
No. of days the partners injected together, past month 1.11 (1.05–1.17) 1.07 (1.01–1.14)
Any receptive needle sharing by at-riska partner with indexb partner, prior month = yes 1.44 (0.14–14.82)
Ancillary equipment sharing at all instances of the partners injecting together, prior month = yes 4.87 (1.45–16.35) 5.32 (1.25–22.70)
Median No. of other injecting partners of the at-riska partner 1.01 (1.00–1.03)
Partners had sexual relationship, prior month = yes 9.74 (2.40–39.48) 7.77 (0.58–103.52)
HCV characteristics of indexb partner (time updated)
Indexb partner in HCV-seronegative viremic phasec 14.84 (2.77–79.48) 28.02 (5.61–139.95)
HCV viremia of indexb partner nearest visit (log10) 1.03 (0.69–1.53)d 0.90 (0.55–1.46)d

Bold indicates statistical significance (P < .05).

Abbreviations: CI, confidence interval; GEE, generalized estimating equation; HCV, hepatitis C virus; OR, odds ratio; PWID, people who inject drugs.

aAt-risk partner: enrolled as either HCV RNA negative or HCV-seronegative viremic.

bIndex partner: enrolled as HCV RNA positive.

cHCV-seronegative viremic phase: indicated by anti-HCV-negative and HCV RNA–positive test results, as well as RNA-positive test results.

dLast value carried forward.